HUE061108T2 - Rákellenes fúziós polipeptid - Google Patents

Rákellenes fúziós polipeptid

Info

Publication number
HUE061108T2
HUE061108T2 HUE16729794A HUE16729794A HUE061108T2 HU E061108 T2 HUE061108 T2 HU E061108T2 HU E16729794 A HUE16729794 A HU E16729794A HU E16729794 A HUE16729794 A HU E16729794A HU E061108 T2 HUE061108 T2 HU E061108T2
Authority
HU
Hungary
Prior art keywords
fusion polypeptide
cancer fusion
cancer
polypeptide
fusion
Prior art date
Application number
HUE16729794A
Other languages
English (en)
Hungarian (hu)
Inventor
Marlon Hinner
Aiba Rachida Bel
Christine Rothe
Shane Olwill
Corinna Schlosser
Original Assignee
Pieris Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pieris Pharmaceuticals Gmbh filed Critical Pieris Pharmaceuticals Gmbh
Publication of HUE061108T2 publication Critical patent/HUE061108T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HUE16729794A 2015-05-18 2016-05-18 Rákellenes fúziós polipeptid HUE061108T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15167927 2015-05-18
EP16150508 2016-01-08

Publications (1)

Publication Number Publication Date
HUE061108T2 true HUE061108T2 (hu) 2023-05-28

Family

ID=56134305

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16729794A HUE061108T2 (hu) 2015-05-18 2016-05-18 Rákellenes fúziós polipeptid

Country Status (22)

Country Link
US (2) US10913778B2 (enExample)
EP (2) EP3298030B1 (enExample)
JP (1) JP6947642B2 (enExample)
KR (1) KR102685748B1 (enExample)
CN (1) CN108112253B (enExample)
AU (1) AU2016262845B2 (enExample)
CA (1) CA2980838A1 (enExample)
DK (1) DK3298030T5 (enExample)
ES (1) ES2938525T3 (enExample)
FI (1) FI3298030T3 (enExample)
HR (1) HRP20230145T1 (enExample)
HU (1) HUE061108T2 (enExample)
LT (1) LT3298030T (enExample)
MX (1) MX390894B (enExample)
PL (1) PL3298030T3 (enExample)
RS (1) RS64002B1 (enExample)
RU (2) RU2754466C2 (enExample)
SG (1) SG11201707426SA (enExample)
SI (1) SI3298030T1 (enExample)
SM (1) SMT202300026T1 (enExample)
WO (1) WO2016184882A1 (enExample)
ZA (1) ZA201706061B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015205530B8 (en) * 2014-01-13 2019-09-19 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
PH12017501583B1 (en) * 2015-05-04 2023-01-20 Pieris Pharmaceuticals Gmbh Novel proteins specific for cd137
MX2018000447A (es) 2015-07-15 2018-08-15 Pieris Pharmaceuticals Gmbh Novedosas proteinas especificas para lag-3.
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
CA3047070A1 (en) * 2017-01-03 2018-07-12 F.Hoffmann-La Roche Ag Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9
EP3565842A1 (en) 2017-01-06 2019-11-13 Crescendo Biologics Limited Single domain antibodies to programmed cell death (pd-1)
JP7225116B2 (ja) * 2017-01-18 2023-02-20 ピエリス ファーマシューティカルズ ゲーエムベーハー Ｌａｇ－３に対する結合親和性を有するリポカリンムテイン
WO2018134279A1 (en) * 2017-01-18 2018-07-26 Pieris Pharmaceuticals Gmbh Novel fusion polypeptides specific for lag-3 and pd-1
CA3082297A1 (en) * 2017-11-13 2019-05-16 Crescendo Biologics Limited Molecules that bind to cd137 and psma
GB201802573D0 (en) 2018-02-16 2018-04-04 Crescendo Biologics Ltd Therapeutic molecules that bind to LAG3
MX2020010015A (es) 2018-03-26 2021-01-15 4Sc Ag Combinacion que comprende inhibidor de hdac y agonista de cd137 para la terapia del cancer.
RS64343B9 (sr) * 2018-07-31 2023-11-30 Pieris Pharmaceuticals Gmbh Novi fuzioni protein specifičan za cd137 i pd-l1
JP7476219B2 (ja) 2019-02-26 2024-04-30 ピエリス ファーマシューティカルズ ゲーエムベーハー Ｃｄ１３７およびｇｐｃ３に特異的な新規融合タンパク質
CN113939307A (zh) * 2019-03-29 2022-01-14 皮里斯制药有限公司 脂质运载蛋白突变蛋白的吸入施用
CN113677403B (zh) * 2019-04-12 2024-12-27 豪夫迈·罗氏有限公司 包含脂质运载蛋白突变蛋白的双特异性抗原结合分子
BR112021021271A2 (pt) * 2019-04-23 2021-12-21 Lg Chemical Ltd Polipeptídeo de fusão compreendendo região fc de imunoglobulina e gdf15
CN114245807B (zh) * 2019-06-25 2025-05-02 吉利德科学公司 Flt3l-fc融合蛋白和使用方法
TWI860386B (zh) * 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
WO2023036043A1 (zh) * 2021-09-09 2023-03-16 广东东阳光药业有限公司 抗癌结合分子及其应用
PE20251544A1 (es) * 2022-09-21 2025-06-05 Seagen Inc Nueva proteina de fusion especifica para cd137 y cd228
WO2026145795A1 (zh) * 2025-01-06 2026-07-09 湖南中晟全肽生物科技股份有限公司 一种gpc3靶向结合多肽及其药物偶联物与应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2032831T5 (es) 1986-08-19 2001-02-16 Genentech Inc Dispositivo y dispersion para suministro intrapulmonar de factores de crecimiento polipeptidos y citoquinas.
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
AU696387B2 (en) 1994-05-18 1998-09-10 Inhale Therapeutic Systems, Inc. Methods and compositions for the dry powder formulation of interferons
DE4417598A1 (de) 1994-05-19 1995-12-14 Max Planck Gesellschaft Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen
WO1996023879A1 (en) 1995-01-30 1996-08-08 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
WO1998016873A1 (en) 1996-10-14 1998-04-23 Firm Forsat Ltd. Method for preparing dispersions of chromogenic components
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
JP3839667B2 (ja) 1998-06-08 2006-11-01 エフ．ホフマン−ラ ロシュ アーゲー 慢性Ｃ型肝炎の処置のためのＰｅｇ−ＩＮＦ−アルファ及びリバビリンの使用
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
AU2001294617A1 (en) 2000-09-21 2002-04-02 University Of Massachusetts Method of inducing apoptosis in lymphoid cells
US7211395B2 (en) 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
US7118915B2 (en) 2001-09-27 2006-10-10 Pieris Proteolab Ag Muteins of apolipoprotein D
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
US7691970B2 (en) 2003-08-25 2010-04-06 Pieris Ag Muteins of a bilin-binding protein with affinity for a given target
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
US7288638B2 (en) * 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
JP2007284351A (ja) 2004-07-27 2007-11-01 Osaka Bioscience Institute アミロイド蛋白質の凝集を抑制する物質とその作用
US7892827B2 (en) 2004-11-26 2011-02-22 Pieris Ag Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
AU2006294644A1 (en) 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
WO2007137170A2 (en) 2006-05-20 2007-11-29 Seattle Genetics, Inc. Anti-glypican-3 antibody drug conjugates
CN101516907B (zh) 2006-08-01 2015-08-26 皮里斯股份公司 泪液脂质运载蛋白的突变蛋白及其获得方法
DE602007009995D1 (de) 2006-08-01 2010-12-02 Pieris Ag Muteine von tearlipocalin und verfahren zu deren gewinnung
AU2008275985B2 (en) 2007-07-17 2013-09-19 E. R. Squibb & Sons, L.L.C. Monoclonal antibodies against Glypican-3
EP2225268B1 (en) 2007-10-19 2012-08-29 Abbott Laboratories Immunoassays and kits for the detection of ngal
US8420051B2 (en) 2008-06-24 2013-04-16 Technische Universitaet Meunchen Muteins of hNGAL and related proteins with affinity for a given target
BR112012013662B1 (pt) 2009-12-07 2022-08-02 Pieris Pharmaceuticals Gmbh Muteínas de lipocalina associada à gelatinase de neutrófilo humano (lcn2, hngal), seu uso e seus métodos de geração e produção, molécula de ácido nucleico, célula hospedeira, composição farmacêutica e kit de diagnóstico ou analítico
AU2011290751B2 (en) 2010-08-16 2015-08-13 Pieris Ag Binding proteins for Hepcidin
NZ729044A (en) * 2010-09-09 2020-07-31 Pfizer 4-1bb binding molecules
CA2817779C (en) 2010-11-15 2019-02-19 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
WO2013174783A1 (en) * 2012-05-23 2013-11-28 Pieris Ag Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3
SG11201504600UA (en) * 2012-12-10 2015-07-30 Hutchinson Fred Cancer Res Methods for screening
EP2948475A2 (en) * 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
CN104140974B (zh) * 2013-05-08 2017-09-29 科济生物医药（上海）有限公司 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞
AU2015205530B8 (en) 2014-01-13 2019-09-19 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
MX380176B (es) * 2014-04-07 2025-03-12 Chugai Pharmaceutical Co Ltd Molecula ligada a antigeno inmunoactivada.
SG11201705278QA (en) 2015-01-28 2017-07-28 Pieris Pharmaceuticals Gmbh Novel proteins specific for angiogenesis
EP3259282A1 (en) 2015-02-18 2017-12-27 Sanofi Novel proteins specific for pyoverdine and pyochelin
RU2727165C2 (ru) 2015-05-04 2020-07-21 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Слитый полипептид с противораковой активностью
PH12017501583B1 (en) 2015-05-04 2023-01-20 Pieris Pharmaceuticals Gmbh Novel proteins specific for cd137
EP3298029A1 (en) * 2015-05-18 2018-03-28 Pieris Pharmaceuticals GmbH Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白

Also Published As

Publication number Publication date
RU2754466C2 (ru) 2021-09-02
AU2016262845B2 (en) 2020-07-23
AU2016262845A1 (en) 2018-01-04
WO2016184882A1 (en) 2016-11-24
EP3298030A1 (en) 2018-03-28
JP6947642B2 (ja) 2021-10-13
MX2017014716A (es) 2018-06-28
RU2017135539A (ru) 2019-06-18
DK3298030T5 (en) 2024-10-07
CN108112253A (zh) 2018-06-01
FI3298030T3 (fi) 2023-02-22
BR112017020445A2 (pt) 2018-07-03
SI3298030T1 (sl) 2023-05-31
RU2017135539A3 (enExample) 2019-11-29
US10913778B2 (en) 2021-02-09
RU2021119777A (ru) 2021-08-16
CN108112253B (zh) 2022-09-23
US20180148485A1 (en) 2018-05-31
DK3298030T3 (en) 2023-02-06
EP4219535A1 (en) 2023-08-02
RS64002B1 (sr) 2023-03-31
LT3298030T (lt) 2023-02-27
KR20180002855A (ko) 2018-01-08
SG11201707426SA (en) 2017-10-30
JP2018519803A (ja) 2018-07-26
US20210403516A1 (en) 2021-12-30
KR102685748B1 (ko) 2024-07-18
MX390894B (es) 2025-03-21
ES2938525T3 (es) 2023-04-12
SMT202300026T1 (it) 2023-03-17
HRP20230145T1 (hr) 2023-04-28
ZA201706061B (en) 2022-05-25
EP3298030B1 (en) 2023-01-18
PL3298030T3 (pl) 2023-05-08
CA2980838A1 (en) 2016-11-24
US11919931B2 (en) 2024-03-05

Similar Documents

Publication Publication Date Title
ZA201705961B (en) Anti-cancer fusion polypeptide
ZA201706061B (en) Anti-cancer fusion polypeptide
IL254965A0 (en) fusion proteins
ZA201802261B (en) Polypeptides
GB201509413D0 (en) Fusion protein
IL254577A0 (en) polypeptides
IL246355A0 (en) p97–ids fused proteins
GB201504691D0 (en) Fusion protein
SG11201706882VA (en) Polypeptides
ZA201704366B (en) Il-17a-binding polypeptides
ZA201606327B (en) Uti fusion proteins
SG10201911499TA (en) Novel anti-angiogenic fusion polypeptides
SG11201606501PA (en) Nanobody-fluorescent protein fusion
ZA201801394B (en) Fusion protein
PL3087179T3 (pl) Polipeptydy fuzyjne związane z omega-hydroksylazą o ulepszonych właściwościach
GB201602850D0 (en) Fusion proteins
PT3298030T (pt) Polipeptídeo de fusão anticancro
GB201713537D0 (en) Fusion Polypeptide
GB201503789D0 (en) Fusion polypeptide
GB201502166D0 (en) Bonding polypeptides
GB201520574D0 (en) Peptides